CCL2 and hyperlipidemia: Furthermore, ipragliflozin improved hyperlipidemia, hepatic steatosis, renal glomerular hyperfiltration, albuminuria, and provided hepatic protection with concomitantly reduced liver levels of oxidative stress biomarkers (thiobarbituric acid reactive substances [TBARS], protein carbonyl) and plasma inflammatory markers (IL-6, TNF-α, monocyte chemotactic protein-1 [MCP-1], and CRP) in T1DM rats [171].